newsfilter
← Latest News
GlobeNewswire·

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA's strong prescription uptake continues: Q1 2024 CAPLYTA total